NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

被引：0
作者：
Munechika Enjoji
Kazuyuki Machida
Motoyuki Kohjima
Masaki Kato
Kazuhiro Kotoh
Kazuhisa Matsunaga
Manabu Nakashima
Makoto Nakamuta
机构：
[1] Fukuoka University,Faculty of Pharmaceutical Sciences
[2] National Hospital Organization,Clinical Research Center, Kyushu Medical Center
[3] National Hospital Organization,Department of Gastroenterology, Kyushu Medical Center
[4] Kyushu University,Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences
来源：
Lipids in Health and Disease | / 9卷
关键词：
Ezetimibe; Nonalcoholic Fatty Liver Disease; NAFLD Patient; Ursodiol; Ezetimibe Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[41]   Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease [J].
Kefala, Georgia ;
Tziomalos, Konstantinos .
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (03) :189-191
[42]   Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients [J].
Mariani, Stefania ;
Fiore, Daniela ;
Basciani, Sabrina ;
Persichetti, Agnese ;
Contini, Savina ;
Lubrano, Carla ;
Salvatori, Luisa ;
Lenzi, Andrea ;
Gnessi, Lucio .
ENDOCRINE, 2015, 49 (03) :711-716
[43]   Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients [J].
Stefania Mariani ;
Daniela Fiore ;
Sabrina Basciani ;
Agnese Persichetti ;
Savina Contini ;
Carla Lubrano ;
Luisa Salvatori ;
Andrea Lenzi ;
Lucio Gnessi .
Endocrine, 2015, 49 :711-716
[44]   Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus [J].
Chen, Ning ;
Zhou, Jingqi ;
Wang, Kai ;
Li, Xiaoying ;
Li, Zhibin .
BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (01)
[45]   Omentin-1 Levels and Non-alcoholic Fatty Liver Disease in Obese Adolescents [J].
Turkkan, Emine ;
Dag, Huseyin ;
Dikker, Okan ;
Dag, Nevin Cetin ;
Kacar, Alper ;
Sazak, Soner .
IRANIAN JOURNAL OF PEDIATRICS, 2021, 31 (05)
[46]   A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice [J].
Saraswathi, Viswanathan ;
Perriotte-Olson, Curtis ;
Ganesan, Murali ;
Desouza, Cyrus V. ;
Alnouti, Yazen ;
Duryee, Michael J. ;
Thiele, Geoffrey M. ;
Nordgren, Tara M. ;
Clemens, Dahn L. .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2017, 42 :149-159
[47]   Increased prevalence of diabetic complications in Japanese patients with type 1 diabetes and nonalcoholic fatty liver disease [J].
Yoneda C. ;
Ogino J. ;
Matsuura H. ;
Haruki T. ;
Suzuki Y. ;
Hashimoto N. .
Diabetology International, 2012, 3 (1) :37-41
[48]   Hepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease [J].
Yilmaz, Yusuf ;
Eren, Fatih ;
Colak, Yasar ;
Senates, Ebubekir ;
Celikel, Cigdem Ataizi ;
Imeryuz, Nese .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (12) :1488-1493
[49]   Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: critical role of liver-adipose axis [J].
Wei Wang ;
Yulin Kong ;
Xia Wang ;
Zhe Wang ;
Chunlei Tang ;
Jinyou Li ;
Qin Yang ;
Yong Q. Chen ;
Shenglong Zhu .
Cell Communication and Signaling, 21 (1)
[50]   Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: critical role of liver-adipose axis [J].
Wang, Wei ;
Kong, Yulin ;
Wang, Xia ;
Wang, Zhe ;
Tang, Chunlei ;
Li, Jinyou ;
Yang, Qin ;
Chen, Yong Q. ;
Zhu, Shenglong .
CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
12345